Sorted By:

Relevance


Week in Review: The Latest from PhRMA

PhRMA  |  Blog Post

Medicare Monday: Following part one earlier this month on the Centers for Medicare & Medicaid Services’ (CMS) Medicare Part B biosimilars reimbursement plan, part two examines the policy’s impact will have on patients and the biopharma marketplace.
http://catalyst.phrma.org/week-in-review-the-latest-from-phrma-december-4-2015

The Value of Innovation in Oncology - Recognizing Emerging Benefits Over Time Executive Summary

PhRMA  |  Report

A new white paper by Boston Healthcare Associates examines how innovative medicines are driving significant progress in the fight against cancer.
https://www.phrma.org/report/the-value-of-innovation-in-oncology-recognizing-emerging-benefits-over-time-executive-summary

Public Supports Coverage of Personalized Medicine

Chartpack  |  From Our Network

In a recent survey, nearly two-thirds of individuals surveyed believe payers should cover personalized medicine tests and treatments.
http://chartpack.phrma.org/personal-medicines-in-development-chartpack/benefiting-patients-and-the-health-care-system/public-supports-coverage-of-personalized-medicine

Week in Review: The Latest from PhRMA

PhRMA  |  Blog Post

A New Way to Picture Progress Against Cancer:  In this guest blog, Jacqueline Ferguson, senior director of Global Oncology Corporate Affairs of Eli Lilly and Company, discusses how value in cancer treatment evolves and advocates for policies that foster the development of innovative medicines.
http://catalyst.phrma.org/week-in-review-the-latest-from-phrma-august-28-2015

4 recommendations for ICER

PhRMA  |  Blog Post

Read more about PhRMA’s policy solutions to promote value-driven health care here.
http://catalyst.phrma.org/4-recommendations-for-icer

As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority

PhRMA  |  Blog Post

Changes to the PMPRB mandate could affect how Canadian pharmaceutical prices are established and benchmarked against pricing in other markets, which could – in turn – potentially hamper patient access to medicines. 
http://catalyst.phrma.org/as-u.s.-looks-to-modernize-nafta-strong-enforcement-of-existing-obligations-should-be-a-top-priority

Prioritizing Patients: A Discussion on Outcomes-Based Care

PhRMA  |  Video

Ubl, President and CEO, PhRMA Cynthia Zagieboylo, President and CEO, National Multiple Sclerosis Society Moderators:  Bob Cusack, Editor-in-Chief, The Hill Kim Dixon, Policy Editor, The Hill
https://www.phrma.org/video/prioritizing-patients-a-discussion-on-outcomes-based-care

PDUFA

PhRMA  |  From PhRMA

Enhances the FDA’s access to the tools, processes and expertise necessary to keep pace with the latest scientific advances in drug development and regulation.
https://www.phrma.org/advocacy/research-development/pdufa

340B Spotlight: Rapid growth of contract pharmacies

PhRMA  |  Blog Post

  Check out our new chart pack and AIR340B’s white paper for more information.
http://catalyst.phrma.org/340b-spotlight-rapid-growth-of-contract-pharmacies

Study finds actual cost of 14 new medicines is billions less than predicted

PhRMA  |  Blog Post

Read more about PhRMA’s policy solutions to deliver innovative treatments to patients here.
http://catalyst.phrma.org/study-finds-actual-cost-of-14-new-medicines-is-billions-less-than-predicted

Director - International Advocacy

PhRMA  |  PhRMA Career

We are committed to supporting our family of professionals at PhRMA and strive to create programs that help our team members manage the challenges of balancing a fast-paced career with their own personal goals.
https://www.phrma.org

The Pharmaceutical Supply Chain: Gross Drug Expenditures Realized by Stakeholder – Study Backgrounder

PhRMA  |  Fact Sheet

Rebates and discounts biopharmaceutical companies pay to PBMs and payers do not directly reduce cost-sharing for these patients.
https://www.phrma.org/fact-sheet/supply-chain-backgrounder

ICER framework threatens to halt continued progress against multiple myeloma

PhRMA  |  Blog Post

While public stakeholders were given only two weeks to provide input on ICER’s 172-page report, that hasn’t stopped them from weighing in.
http://catalyst.phrma.org/icer-framework-threatens-to-halt-continued-progress-against-multiple-myeloma

ASCO’s Framework: Value at the Crossroads

PhRMA  |  Blog Post

Failure to capture these nuances also increases the risk of the framework being misapplied by policy-makers.
http://catalyst.phrma.org/ascos-framework-value-at-the-crossroads

Driving innovation through collaboration

PhRMA  |  Blog Post

Click .deloitte.com/us/en/pages/life-sciences-and-health-care/articles/how-biopharma-collaborations-are-fueling-biomedical-innovation.html?
http://catalyst.phrma.org/driving-innovation-through-collaboration

340B Spotlight: A Look at 340B Purchases

PhRMA  |  Blog Post

[1] http://www.aha.org/research/policy/infographics/340b.shtml Get instant updates on issues you care about - here.
http://catalyst.phrma.org/340b-spotlight-a-look-at-340b-purchases

Edward Abrahams, Ph.D.

PhRMA  |  Biography

Abrahams serves on the editorial board of Personalized Medicine and has also taught history and public policy at Brown University and the University of Pennsylvania.
https://www.phrma.org/biography/edward-abrahams-ph-d

Senior Director of Talent Acquisition and the Employee Experience – Human Resources

PhRMA  |  PhRMA Career

We are committed to supporting our family of professionals at PhRMA and strive to create programs that help our team members manage the challenges of balancing a fast-paced career with their own personal goals.
https://www.phrma.org

Tom Berger

PhRMA  |  Biography

Berger is responsible fordeveloping and presenting Congressional testimony and position papers on veterans’ benefits, healthcare, mental health, and substance abuse issues.
https://www.phrma.org/biography/tom-berger

Real-World Evidence

PhRMA  |  Fact Sheet

RWE can come from a variety of sources, including electronic health records, payer administrative claims and patient registries.
https://www.phrma.org/fact-sheet/real-world-evidence

Video: What is a results-based contract?

PhRMA  |  Blog Post

As a result of these arrangements, payers can make a medicine more accessible to patients and biopharmaceutical companies agree to share the financial risk and be reimbursed based on how well medicines work for patients. 
http://catalyst.phrma.org/video-what-is-a-results-based-contract

PhRMA Statement on Human Brain Mapping Initiative

PhRMA  |  Press Release

For this reason, a consistent public policy framework is needed to provide an environment that is conducive to advance biopharmaceutical research and discovery.
https://www.phrma.org/press-release/phrma-statement-on-human-brain-mapping-initiative

Zika Virus: Current Outbreak and Ongoing Research Efforts

PhRMA  |  Report

Symptoms of the disease are usually mild, including fever, joint pain, rashes, and viral conjunctivitis (red/itchy eyes), and appear within a week of being exposed.
https://www.phrma.org/report/zika-virus-current-outbreak-and-ongoing-research-efforts

Week in Review: The Latest from PhRMA

PhRMA  |  Blog Post

PhRMA’s own Sharon Brigner noted she’s found a rewarding career advocating for patients at the bedside and at the policy table.
http://catalyst.phrma.org/week-in-review-the-latest-from-phrma

21st Century Cures: Digital Health Care

PhRMA  |  Speeches & Communication

The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the opportunity to provide input to the House Energy and Commerce Committee in response to the white paper entitled “21st Century Cures – Digital Health Care: Leveraging Technology to Advance the Discovery, Development, and Delivery of Better Treatments and Cures.”
https://www.phrma.org/public-communication/21st-century-cures-digital-health-care

You have reviewed the first 300 results out of 1102. Each page contains 25 results. You're on page 12.

prev 7 8 9 10 11 12 next